What Pancragen is
Pancragen is the tetrapeptide KEDW, marketed as a pancreatic “bioregulator.” It is not insulin or an approved diabetes medicine and has no FDA-approved product or dose.
The small human study is insufficient
A 2011 report compared 30 healthy older people with 33 older people with type 2 diabetes and reported changes in fasting glucose, glucose tolerance, insulin, and an insulin-resistance index after Pancragen.[1] The brief report does not provide the scale, independent replication, or modern randomized evidence needed to establish diabetes treatment. Animal and cell-culture studies add biological hypotheses, not proof.[2]
Safety and treatment-substitution risks
No comprehensive adverse-event, interaction, pregnancy, kidney, liver, cardiovascular, hypoglycemia, or long-term safety program exists. Using an unapproved peptide in place of established diabetes care could delay effective treatment and monitoring.
Regulatory status
Pancragen is unapproved in the United States. Compounded drugs are not FDA-approved or premarket-verified for safety, effectiveness, or quality.[3] Teloryx publishes no dose or preparation protocol.